Welcome to International Network for Natural Sciences | INNSpub

Paper Details

Research Paper | April 1, 2011

| Download 5

Pro-inflammatory cytokine Interleukin-1 beta is associated with cardiovascular fitness in sedentary diabetic patients

Eizadi Mojtaba, Sohaily Shahram, Parsian Heshmatolah, Zand Alireza

Key Words:

J. Bio. Env. Sci.1( 2), 37-44, April 2011


JBES 2011 [Generate Certificate]


To determine the relationship of interleukin-1 beta (IL-1β) to cardiovascular fitness and lipid profile in type II diabetic. Fasting blood samples were collected in 38 sedentary adult men with type II diabetic (age 38 ± 5 years, body mass index: 31 ± 3 Kg). After overnight fast in order to measuring IL-1b and lipid profile as total cholesterol (TC), triglyceride (TG), low and high density lipoprotein (LDL, HDL). Maxima oxygen consumption was measured by a stepwise incremental bicycle test. Pearson correlations were used to establish the relationship between variables. Serum IL-1β concentration was negatively related to VO2max and positively related with TC, TG, LDL and resting heart rate (p < 0.05). Fasting serum IL-1b was not correlated with HDL (p = 0.214). In conclusion, our data demonstrate a relationship between cardiovascular fitness and systemic inflammation in diabetic patients. These finding suggests a sedentary lifestyle and low cardiovascular fitness is associated with increased IL-1β and systemic inflammation.


Copyright © 2011
By Authors and International Network for
Natural Sciences (INNSPUB)
This article is published under the terms of the Creative
Commons Attribution Liscense 4.0

Pro-inflammatory cytokine Interleukin-1 beta is associated with cardiovascular fitness in sedentary diabetic patients

Abramson JL, Vaccarino V. 2002. Relationship between physical activity and inflammation among apparently healthy middle-aged and older US adults. Arch Intern Med 162, 1286-1292.

Adamopoulos S, Parissis J, Karatzas D. 2002. Physical training modulates proinflammatory cytokines and the soluble Fas/soluble Fas ligand system in patients with chronic heart failure,” Journal of the American College of Cardiology 39(4), 653– 663.

Balducci S, Zanuso S, Nicolucci A, Fernando F, Cavallo S, Cardelli P. 2008. Anti-inflammatory effect of exercise training in subjects with type 2 diabetes and the metabolic syndrome is dependent on exercise modalities and independent of weight loss. Nutr Metab Cardiovasc Dis 20(8), 608-17.

Barrett-Connor E, Grundy SM, Holdbrook MJ. 1982. Plasma lipids and diabetes mellitus in an adult community. Am J Epidemiol. 115, 657-663.

Dasu MR, Devaraj S, Jialal I. 2007. High glucose induces IL-1beta expression in human monocytes: mechanistic insights. Am J Physiol Endocrinol Metab 293(1), 337-46.

Fallon KE, Fallon SK, Boston T. 2001. The acute phase response and exercise: court and field sports. Br J Sports Med 35, 170-173.

Galic S, Oakhill JS, Steinberg GR. 2010. Adipose tissue as an endocrine organ. Mol Cell Endocrinol 316(2), 129-39.

Gielen S, Adams V, obius-Winkler SM. 2003. Anti-inflammatory effects of exercise training in the skeletal muscle of patients with chronic heart failure,” Journal of the American College of Cardiology 42(5), 861–868.

Gomez-Merino D, Drogou C, Guezennec CY, Chennaoui M. 2007. Effects of chronic exercise on cytokine production in white adipose tissue and skeletal muscle of rats. Cytokine 40(1), 23-9.

Gu K, Cowie CC, Harris MI. 1998. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993. Diabetes Care 21,1138-1145.

Juge-Aubry     CE,  Somm  E,  Giusti  V. 2003. Adipose tissue is a major source of interleukin-1 receptor antagonist: upregulation in obesity and infl ammation. Diabetes 52, 1104 -10.

Kershaw EE, Flier JS. 2004. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89, 2548– 2556.

Lamonte MJ, Blair SN, Church TS. 2005. Physical activity and diabetes prevention. J Appl Physiol 99, 1205-1213.

Lazar MA. 2005. How obesity causes diabetes: not a tall tale. Science 307, 373–375.

Maedler K, Dharmadhikari G, Schumann DM, Størling J. 2009. Interleukin-1 beta targeted therapy for type 2 diabetes. Expert Opin Biol Ther 9(9),1177-88.

Manica-Cattani MF, Bittencourt L, Rocha MI, Algarve TD, Bodanese LC, Rech R. 2010. Association between interleukin-1 beta polymorphism (+3953) and obesity. Mol Cell Endocrinol 314(1), 84-9.

Matsuki T, Horai R, Sudo K, Iwakura Y. 2003. IL-1 plays an important role in lipid metabolism by regulating insulin levels under physiological conditions. J Exp Med 198(6), 877-88.

Mullis R, Campbell IT, Wearden AJ, Morriss RK, Pearson DJ. 1999. Prediction of peak oxygen uptake in chronic fatigue syndrome”. Br J Sports Med 33(5), 352-6.

Myers J, Kaykha A, George S. 2004. Fitness versus physical activity patterns in predicting mortality in men. Am J Med 117, 912-918.

Nadeau KJ, Zeitler PS, Bauer TA, Brown MS, Dorosz JL, Draznin B et al. 2009. Insulin resistance in adolescents with type 2 diabetes is associated with impaired exercise capacity. J Clin Endocrinol Metab 94(10), 3687-95.

Osborn O, Brownell SE, Sanchez-Alavez M, Salomon D, Gram H, Bartfai T. 2008. Treatment with an Interleukin 1 beta antibody improves glycemic control in diet-induced obesity. Cytokine 44(1), 141-8.

Petersen AM, Pedersen BK. 2006. The role of IL-6 in mediating the anti-inflammatory effects of exercise. J Physiol Pharmacol 57(10), 43-51.

Sauter  NS, Schulthess FT, Galasso R. 2008. The antiinfl amatory cytokine interleukin-1 receptor antagonist protects from high-fat diet-induced hyperglycemia. Endocrinology 149, 2208 – 18.

Sell H, Dietze-Schroeder D, Eckardt K, Eckel J. 2006. Cytokine secretion by human adipocytes is differentially regulated by adiponectin, AICAR, and troglitazone. Biochem Biophys Res Commun 343, 700–706.

Thune I, Furberg AS. 2011. Physical activity and cancer risk: dose-response and cancer, all sites and site-specific. Med Sci Sports Exerc; 33, 530-550.

Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen E, Pyorala K. 1993. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia 36, 1175-1184.